Technical Analysis for SPRC - SciSparc Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | -1.10% | |
| Outside Day | Range Expansion | -1.10% | |
| Fell Below 20 DMA | Bearish | 3.14% | |
| NR7 | Range Contraction | 3.14% | |
| NR7-2 | Range Contraction | 3.14% | |
| Doji - Bullish? | Reversal | 3.14% | |
| Gapped Down | Weakness | 3.14% | |
| Crossed Above 20 DMA | Bullish | 0.04% | |
| NR7 | Range Contraction | 0.04% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 19 hours ago |
| Down 5% | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 3% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
SciSparc Ltd. Description
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Biology Pain Neuroscience Alzheimer's Disease Drug Development Dementia Epilepsy Amyloidosis Sleep Apnea Obstructive Sleep Apnea Autism Spectrum Disorder Status Epilepticus Tourette Syndrome Treatment Of Autism Spectrum Disorder Treatment Of Tourette Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.2199 |
| 52 Week Low | 0.2055 |
| Average Volume | 1,403,362 |
| 200-Day Moving Average | 1.39 |
| 50-Day Moving Average | 0.27 |
| 20-Day Moving Average | 0.23 |
| 10-Day Moving Average | 0.24 |
| Average True Range | 0.02 |
| RSI (14) | 45.65 |
| ADX | 24.59 |
| +DI | 25.24 |
| -DI | 12.37 |
| Chandelier Exit (Long, 3 ATRs) | 0.23 |
| Chandelier Exit (Short, 3 ATRs) | 0.28 |
| Upper Bollinger Bands | 0.26 |
| Lower Bollinger Band | 0.20 |
| Percent B (%b) | 0.53 |
| BandWidth | 28.88 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0046 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.26 | ||||
| Resistance 3 (R3) | 0.26 | 0.25 | 0.25 | ||
| Resistance 2 (R2) | 0.25 | 0.25 | 0.25 | 0.25 | |
| Resistance 1 (R1) | 0.24 | 0.24 | 0.24 | 0.24 | 0.25 |
| Pivot Point | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
| Support 1 (S1) | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 |
| Support 2 (S2) | 0.22 | 0.23 | 0.22 | 0.21 | |
| Support 3 (S3) | 0.21 | 0.22 | 0.21 | ||
| Support 4 (S4) | 0.21 |
